Telangana: Drugs Control Administration, Telangana, has seized Spurious Drugs (Counterfeit Versions) ‘Montek-LC’ Tablets (Montelukast Sodium and
Levocetirizine Hydrochloride Tablets), falsely claimed to be manufactured by
Sun Pharma Laboratories Ltd.Based on intelligence gathered by Drugs Control Administration officials,
raids were conducted at several dealers in Hyderabad, leading to the detection
of Spurious Drugs (Counterfeit Versions) ‘Montek-LC’ Tablets (Montelukast
Sodium and Levocetirizine Hydrochloride Tablets) circulating in the market.‘Montek-LC’ Tablets are used in the management of signs and symptoms
of allergic rhinitis, chronic idiopathic urticaria and bronchial asthma.
During the raids, Drugs Inspectors detained the stocks and obtained a
comparison statement for the suspected batches from the original
manufacturer, Sun Pharma Laboratories Ltd., with the original batches. The
manufacturer also concluded that the batch of ‘Montek-LC’ Tablets
(Montelukast Sodium and Levocetirizine Hydrochloride Tablets) detained by
the Drugs Control Administration were “Spurious Drugs/Counterfeit Drugs”.
“During the raid conducted on 18th March, 2025 at Sri Nirmala Pharma,
H.No: 8-3-60, Second Bazar, Secunderabad, seized a counterfeit version of
‘Montek-LC’ Tablets (Montelukast Sodium and Levocetirizine Hydrochloride
Tablets), Batch No.: SIE1910A, Mfg. Date: 07/2023, Exp. Date: 12/2025, falsely
claimed to be manufactured by Sun Pharma Laboratories Ltd., Plot No.107-
108, Namli Block, P.O Ranipool, East- SikkimCounterfeit Version of ‘Montek-LC’ Tablets (Montelukast Sodium and
Levocetirizine Hydrochloride Tablets), Batch No.: SIE1910A Seized by DCA,” the release stated.Smt. D. Saritha, Assistant Director, Secunderabad, Sri. M. Surendranath,
Drugs Inspector, Begumpet and Smt. P. Renuka, Drugs Inspector, Musheerabad
carried out the raids.
Further investigation will be conducted, and appropriate action will be
taken against all offenders.
Spurious drugs pose a significant threat to public health, endangering
patients’ well-being. These drugs not only fail to treat the intended disease but
also can lead to severe health complications over time. DCA is actively working
to ensure the removal of spurious drugs from the market.